Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 105-113

  Doménech, Monica ^a   Coca, Antonio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antihypertensive fixed dose triple therapy; Blood pressure control; Hypertension treatment

Indexed keywords

EID: 77954593705     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Ong KL, Cheung BM, Man YB, Lau CP, Lam HS. Prevalence, awareness, treatment, and control of hypertension among United States adults (1999-2004). Hypertension. 2007;49:69-75.
2. Milani RV. Reaching for aggressive blood pressure goals: Role of angiotensin receptor blockade in combination therapy. Am J Manag Care. 2005;11(7 Suppl):S220-S227.
3. Cusham WC, Ford CE, Cutler JA, et al. Success and prediction of blood pressure control in diverse North American Settings: the hypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
5. Alleman Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with uncontrolled hypertension with previous monotherapy: The Exforge in previous failure after single therapy (EX-fast) study. J Clin Hypertens. 2008;10:185-194.
6. Pool JL, Glazer R, Weinberger M, Alvarado M, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 versus monotherapy: a double blind placebo controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.
7. Dezii CM. A retrospective study of persistence with single pill combination therapy vs concurrent two pill therapy in patients with hypertension. Manag Caree. 2000;9(9 Suppl):2-6.
8. Product information. http://www.emea.europea.eu
9. Assessment report for Exforge HCT. International non-proprietary name: amlodipine besylate/valsartan/hydrochlorothiazide). http://www. emea.europea.eu
10. European Medicines Agency (EMEA). Summary of product characteristics: Exforge® (Amlodipine/Valsartan) filmcoated tablets. http://www.emea.europea.eu
11. EuropeanMedicines Agency (EMEA). Summary of product characteristics: Co-diovan® (Valsartan/Hydrochlorothiazide). http://www.emea. europea.eu
12. Plosker GL, Robinson DM. Amlodipine/valsartan f ixed dose combination in hypertension. Drugs. 2008;68:373-381.
13. Calhoun DA, Lacourciere Y, Chiang TY, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan and hydrochlorothiazide: A randomized clinical trial. Hypertension. 2009;54:32-39.
14. Elijovich F, Laffer C. A role for single pill triple-therapy in hypertension. Ther Adv Cardiovasc Dis. 2009;3:231-240.
15. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2157.
16. Nasser SA, Lai Z, O'Connor S, Liu X, FlacK JM. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr Hypertens Rev. 2008;10:398-404.
17. Black HR. Triple fixed-dose combination therapy: back to the past? Hypertension. 2009;54:19-22.